Clinical Trials Logo
  1. Home
  2. Opioid-induced Constipation
  3. NCT01207427

Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain

Opioid Induced Constipation Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain

Clinical Trial Summary

Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract. The most common symptoms associated with the effects of opioids are constipation and nausea and/or vomiting. Moreover, constipation is a common and distressing side effect of long-term opioid therapy.

The primary objective of this study was to compare ADL5945, a MOR antagonist, with placebo in the treatment of opioid-induced constipation (OIC) in adults taking long-term opioid therapy for chronic noncancer pain.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01207427
Study type Interventional
Source Cubist Pharmaceuticals LLC
Contact
Status Completed
Phase Phase 2
Start date October 14, 2010
Completion date June 28, 2011
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02813369 - Naloxegol Health Outcome Post Authorisation Safety Study
Completed NCT01957046 - A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Phase 4
Completed NCT01401985 - A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) Phase 2
Completed NCT00984334 - Naloxone SR Capsules in Patients With Opioid Induced Constipation Phase 2
Completed NCT01459926 - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation Phase 2
Terminated NCT01117051 - Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation Phase 3
Completed NCT03060512 - To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Phase 4
Completed NCT01109511 - A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy Phase 4
Active, not recruiting NCT02813356 - Naloxegol US PMR CV Safety.
Completed NCT01812733 - Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives N/A
Completed NCT01623609 - Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol Phase 1
Completed NCT02813148 - Naloxegol Drug Utilization Post Authorisation Safety Study
Completed NCT01443403 - A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy Phase 2
Completed NCT03638440 - Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.